SomaLogic Founder, Dr. Larry Gold, receives lifetime achievement award

BOULDER, Colo. (April 14, 2021)—Dr. Larry Gold, the founder of SomaLogic, was awarded the Lifetime Achievement Award on behalf of the International Society on Aptamers (INSOAP) for his pioneering and extraordinary contributions to the field of aptamers and therapeutics.

Dr. Gold has been a professor at the University of Colorado at Boulder since 1970. While at the University, he served as the Chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. Between 1995 and 2013, Dr. Gold received the University of Colorado Boulder Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, the Lifetime Achievement Award from the Colorado Biosciences Association, and the Chiron Prize for Biotechnology. Dr. Gold was also awarded the 8th International Steven Hoogendijk Prize by the Dutch Batavian Society of Experimental Philosophy in 2018.

Dr. Gold has been a member of the American Academy of Arts and Sciences since 1993 and the National Academy of Sciences since 1995. He is also fellow of the National Academy of Inventors. Dr. Gold serves on the Board of Directors for CompleGen, Plato BioPharma, Lab79, Keck Graduate Institute and the Biological Sciences Curriculum Study.


About SomaLogic
SomaLogic seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s precise, proprietary, and personalized measurement of important changes in an individual’s proteins over time.

For more information, visit and follow @somalogic on Twitter.

SomaSignal™ tests are developed and performance characteristics determined by SomaLogic, Inc., and SomaLogic is a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. SomaSignal™ tests have not been cleared or approved by the US Food and Drug Administration. 

Forward Looking Statements Disclaimer
Certain matters discussed throughout this news release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, our use of words such as “expect,” “anticipate,” “estimate,” “believe,” “should,“ “intend,” “strategy,” “future,” “opportunity,” “will,” “forecast,” “plan,” “project,” “assume” or similar words of futurity identify such forward-looking statements. These forward-looking statements are based on current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such statements may relate to projections of the Company’s revenue, earnings and other business plans, financial and operational measures, Company debt levels, ability to repay outstanding indebtedness, payment of dividends, and future operations, among other matters. We caution you not to place undue reliance on any such forward-looking statements. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Forward-looking statements speak only as of the date they are made. You are cautioned not to put undue reliance on forward-looking statements.

SomaLogic Contact
Emilia Costales

Sign up to receive our news releases